Alyeska Investment Group L.P. Invests $26.01 Million in Sarepta Therapeutics Inc (SRPT) Stock
Alyeska Investment Group L.P. acquired a new stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm acquired 573,440 shares of the biotechnology company’s stock, valued at approximately $26,011,000. Alyeska Investment Group L.P. owned about 0.89% of Sarepta Therapeutics as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of the business. Ameritas Investment Partners Inc. increased its stake in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $204,000. Bayesian Capital Management LP purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $206,000. Finally, Strs Ohio purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $208,000. Hedge funds and other institutional investors own 82.02% of the company’s stock.
Sarepta Therapeutics Inc (NASDAQ SRPT) opened at $54.26 on Friday. Sarepta Therapeutics Inc has a one year low of $26.26 and a one year high of $57.57. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The business had revenue of $45.95 million during the quarter, compared to analyst estimates of $41.29 million. During the same period in the previous year, the business earned ($0.95) EPS. research analysts forecast that Sarepta Therapeutics Inc will post -3.11 EPS for the current fiscal year.
In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now directly owns 13,333 shares in the company, valued at approximately $745,181.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Shamim Ruff sold 10,000 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the transaction, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at $2,037,475. The disclosure for this sale can be found here. Insiders sold a total of 28,167 shares of company stock valued at $1,497,619 over the last quarter. 9.60% of the stock is owned by company insiders.
SRPT has been the subject of several research analyst reports. Nomura restated a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. Robert W. Baird restated an “outperform” rating and set a $101.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Barclays initiated coverage on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. They set an “equal weight” rating and a $46.00 price target for the company. Finally, Credit Suisse Group raised their price target on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an “outperform” rating in a research note on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have given a buy rating to the company’s stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and an average price target of $64.14.
WARNING: “Alyeska Investment Group L.P. Invests $26.01 Million in Sarepta Therapeutics Inc (SRPT) Stock” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/alyeska-investment-group-l-p-invests-26-01-million-in-sarepta-therapeutics-inc-srpt-stock/1755447.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.